Format

Send to

Choose Destination
R I Med J (2013). 2013 Feb 1;96(2):16-8.

ProThera Biologics, Inc.: a novel immunomodulator and biomarker for life-threatening diseases.

Author information

1
President and chief scientific officer of ProThera Biologics. He is an assistant professor of medicine at the Warren Alpert Medical School of Brown University and a research oncologist in the Carcinogenesis Lab at Rhode Island Hospital.

Abstract

ProThera Biologics is a development stage bio-therapeutics company in East Providence, Rhode Island. The company was founded in 2002 to focus on the critical role and commercial potential of Inter-alpha Inhibitor Proteins (IAIP) for treating acute life-threatening inflammatory diseases. The discovery research originated in the basic research laboratories of the co-founders, Yow-Pin Lim, MD, PhD, and Douglas C. Hixson, PhD, at Rhode Island Hospital, a Lifespan partner. The company is backed by the Slater Technology Fund and has received research grants from the Rhode Island State Science and Technology Council (RI STAC) as well as continuous funding from the National Institutes of Health (NIH), with several Phase I and II Small Business Innovation Research (SBIR) grants over the past 10 years. ProThera has developed a novel process to purify Inter-alpha Inhibitor Proteins from source material, and has conducted groundbreaking research into the usage of IAIP to fight systemic inflammation.

KEYWORDS:

anthrax; inter-alpha inhibitor proteins; sepsis; septic shock

PMID:
23641420
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center